Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Metrics to compare | NVAX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVAXPeersSector | |
---|---|---|---|---|
P/E Ratio | 2.3x | −1.7x | −0.5x | |
PEG Ratio | 0.01 | 0.00 | 0.00 | |
Price/Book | −14.9x | 0.5x | 2.6x | |
Price / LTM Sales | 0.9x | 4.2x | 3.1x | |
Upside (Analyst Target) | 101.7% | 150.3% | 51.1% | |
Fair Value Upside | Unlock | 33.6% | 8.9% | Unlock |